What is Appesat?

Appesat is a Certified Medical Device in capsule form that reduces a person’s appetite, making them feel fuller for longer. It is non-prescription treatment containing Bioginate Complex™ - a fibre complex extracted from the seaweed Laminaria Digitata. Appesat is a clinically proven appetite suppressant.

How to buy Appesat

The Online Clinic is prepared to supply Appesat after we have established that it is an appropriate treatment. Please complete a weight loss consultation that will be reviewed by one of our doctors. We may also offer prescription weight management medications so that you have a choice. The price for a box of 50 capsules is £29.95.

Free Online Assessment Quick and Without Obligation

How does Appesat work?

APPEsat is taken before food and expands to stimulate sensors in the stomach wall, which then causes the body to send a signal to the brain indicating that the stomach is full.

The capsules release lyophilised alginate bodies, which expand in the stomach and stay stable in the acidic environment of the stomach. These alginate bodies stimulate the mechanoresceptors in the stomach wall and as they are not broken down by stomach acid, a feeling of satiety for a prolonged period is achieved. The compound then dissolves in the small intestine after it passes through the stomach undigested.

As users of Appesat feel fuller for longer and want to eat less, they learn new eating patterns that can be maintained in the longer term.

Is Appesat effective?

Appesat is a Certified Medical Device so it has been through a clinical trial to demonstrate safety and efficacy.

In a randomised double blind clinical trial involving 139 patients who were given three Appesat capsules 3 times a day, along with nutritional advice and counselling, the following results were observed after 12 weeks:

  • 77% of patients taking Appesat felt fuller during the treatment, compared with 54.1% in the placebo control group.
  • Patients in the Appesat group lost 9.4 kg, compared with 5.6 kg in the control group taking the placebo.

Is Appesat Safe?

The most common side effects were gastro-intestinal problems, while a small group of people reported dizziness and headache. Generally, Appesat is well tolerated. As Appesat is not absorbed into the blood stream it is not classed as a medication and is therefore significantly less likely to cause side effects than prescription weight loss products.

Drug Interactions

Appesat does not interact with pharmaceutical products. We do recommend that any existing treatments be taken at least one hour before Appesat as it may affect the absorption of medications. If a very precise dosage of medication is required, please consult your prescribing doctor before taking Appesat.


Appesat should not be taken if you have a known hypersensitivity to one or more of its ingredients. If you have any gastrointestinal diseases such as inflammation or ulcers, you should not take Appesat. If you have had a gastric band or gastric balloon fitted, we advise against using Appesat.

Free Online Assessment Quick and Without Obligation

Slimming Pill News

  • Contrave Applies for European License

    A couple of months ago we reported that Orexigen would be submitting an application for a marketing authorisation to the European Medicines Agency for Contrave, its obesity medication. That submission has now happened and the EMA will be accepting interim results from the company's cardiovascular…

    Read full article >
  • Contrave to Apply for European License

    It is a while since we last reported on Contrave, the experimental weight loss medication concocted by Orexigen Therapeutics from two existing medications: bupropion and naltrexone.  The medication met the FDA's minimum efficacy requirements for a weight loss medication, even although the…

    Read full article >
  • Contrave May be Approved Earlier than Expected

    We previously reported that Contrave could gain approval from the FDA if Orexigen Therapeutics were able to demonstrate in a clinical trial that the treatment was not related to cardiovascular problems. Orexigen has now stated that recent discussions with the FDA have made them optimistic about…

    Read full article >
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more Close